Lipocine Inc. - LPCN Real Price to Acquire Entire Company

Lipocine Corporation - graphic logo of issuer LPCN

Lipocine Inc. (LPCN) focuses on developing innovative treatments for endocrine pathologies, leveraging intensive research and development. The business model is based on the implementation of the LIPPRO system to create tablet-based medications designed to replace injections in the men's health segment. The current enterprise value is -11.24. This chart illustrates the valuation dynamics, supplementing data on the company's compliance with environmental standards and bioethics.

LPCN (lipocine.com) Total Company Value history from 11/23/2025 to 10/28/2026

Lipocine Inc. (LPCN) - metric breakdowns and financial figures

- price and consensus price forecast:
Quote Chart Lipocine Inc|LPCN - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Lipocine|LPCN - Total Company Value
- book capitalization data:
Equity per Share Lipocine|LPCN - Company Book Value|Market Capitalization to Net Assets lipocine.com|LPCN - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Lipocine Inc.|LPCN - Long-Term Debt to Capital|Short-Term Debt to Capital lipocine.com|LPCN - Company Debts|Debt to Net Assets Ratio Lipocine|LPCN - Company Long-Term Debt|Company Current Liabilities Lipocine
Comprehensive company analysis:Lipocine Inc (LPCN)
Original product of Lipocine Inc.

Assessing the margin of safety for Lipocine Inc. (LPCN) requires an analysis of the total enterprise value. The EV metric aggregates market capitalization and debt, subtracting cash to determine the actual acquisition price of the company. By analyzing historical EV levels, an investor can identify whether assets are overvalued or undervalued. Such a detailed calculation is critically important given the company's significant pricing power derived from its unique oral hormone delivery platform.

Competitor analysis for Lipocine Inc.

Full Business Value Ascendis Pharma AS ASND|MDGL: Enterprise Value|CORT: Real Price to Acquire Entire Company|Total Company Value Rhythm Pharmaceuticals|AKRO (akerotx.com) - Business Value|Total Company Value Metsera MTSR|Full Business Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Enterprise Value|Value Adjusted for Debt and Cash NewAmsterdam Pharma Corp (NAMS)|Enterprise Value SLNO (Soleno Therapeutics)|amicusrx.com - Enterprise Value|Total Company Value 89bio (ETNB)|AGIO: Value Adjusted for Debt and Cash|GPCR (Structure Pharma) - Total Company Value|MiMedx Corp (MDXG) - Real Price to Acquire Entire Company|RZLT (Rezolute, Inc.) - Enterprise Value|Enterprise Value lexpharma.com (LXRX)|MBX Biosciences (MBX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Total Company Value|Real Price to Acquire Entire Company Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Enterprise Value|biomeafusion.com (BMEA) - Total Enterprise Value|QNCX - Real Price to Acquire Entire Company|Fractyl Health Inc. (GUTS) - Aggregate Business Value|VTVT (vTv Therapeutics, Inc.) - Enterprise Value|Enterprise Value Agape ATP Corp.|Enterprise Value Pluri Inc. (PLUR)|Total Company Value SYBX (synlogictx.com)|MTNB: Total Company Value|sprucebiosciences.com - Total Enterprise Value|GLTO - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value